Of interest, RCC patients with wild type VHL along with TP53 and FLT1 mutations were shown to be related with shorter progression-free survival (PFS) in response to VEGF-targeted treatments, compared to RCC patients with genetic abnormalities of the VHL gene. Here, VEGFA is linked to renal cell carcinoma.